explore -WSS

explore

author：knowledge 2025-09-28 14:50:01 - browse：62

Christine Kao/STAT

The Food and Drug Administration’s approval on Friday of two gene therapies for sickle cell disease sets up what could be an intense competition between Bluebird Bio, maker of Lyfgenia, and the partnership of Vertex Pharmaceuticals and CRISPR Therapeutics, whose drug is Casgevy.

For the first time, physicians and patients will have a choice of potentially curative treatments for an inherited disease that affects nearly 100,000 Americans.

The Vertex/CRISPR team would seem to have the edge. As the first CRISPR-based therapy, Casgevy has the advantage of being powered by the latest and buzziest biological technology, though some physicians and patients may be more comfortable with the lentiviral vector technology behind Lyfgenia, which dates back to the 1990s — even with a “black box” warning of a risk of blood cancer added to its label.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： FDA cancer chief on how to get things done: ‘Don’t tell anybody'

hotspot

WSS

FTC falls short on scrutinizing hospital mergers, study says

Publishing genetic code of viruses could cause disaster

Cue Health's Covid

Healthy food access boosts outcomes in two studies

Cancer researcher Catriona Jamieson is sending tumors into space

Cancer diagnosis changes perspective doctor, former hospital CEO

hotspot

explore

explore

State Dept. review finds Biden bears some blame for Afghanistan failures

Publishing genetic code of viruses could cause disaster

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Carbon Health diabetes program, a test of data

Dobbs anniversary: the lost opportunity of abortion as health care

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

A letter from the executive editor: STAT UnitedHealth investigation

Medicare proposal to cover medical devices draws a mixed reaction

A letter from the executive editor: STAT UnitedHealth investigation

explore

First transplant of an entire human eye performed

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

Health care needs a new profession: neuroimaging counseling

Close Medicare's dangerous gaps in addiction treatment coverage

MassMutual is introducing free genetic testing for members

Cholera vaccine supply gets boost as demand surges globally

explore

leisure time

hotspot

explore